---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069029"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:22:26.931148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Longeveron reports H1 2024 net loss down 27%; Lomecel-B gets RMAT/Fast Track for Alzheimer's

## Summary
- H1 2024 net loss $7.5M (down 27% YoY from $10.3M); revenue $1.0M (up 105% YoY from $0.5M).
- Cash $12.4M at June 30; July capital raises gross $15.3M (Registered Direct $9.0M, warrant exercises $6.3M); runway through Q4 2025.
- FDA granted RMAT and Fast Track for Lomecel-B in mild Alzheimer's after positive Phase 2a CLEAR MIND data at AAIC.
- Phase 2b HLHS trial (ELPIS II) at 70% enrollment; targeting completion by end of 2024.
- Launched CDMO business; expects $4-5M annual revenue once fully operational.

## SEC filing metadata
- accession: 0001213900-24-069029
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390024069029/0001213900-24-069029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390024069029/ea0211362-8k_longe.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069029
- JSON: https://secwatch.observer/filing/0001213900-24-069029.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.